Next Article in Journal
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)
Previous Article in Journal
The Tumour Microenvironment and Epigenetic Regulation in BRCA1 Pathogenic Variant-Associated Breast Cancers
 
 
Reply published on 26 November 2024, see Cancers 2024, 16(23), 3952.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Comment

Comment on Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416

1
Oral Diagnosis and Medicine, Faculty of Dental Medicine, Graduate School of Dental Medicine, Hokkaido University, Kita-13 Nishi-7, Kita-ku, Sapporo 060-8586, Japan
2
Microbiology, Faculty of Dental Medicine, Graduate School of Dental Medicine, Hokkaido University, Kita-13 Nishi-7, Kita-ku, Sapporo 060-8586, Japan
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(23), 3911; https://doi.org/10.3390/cancers16233911
Submission received: 11 October 2024 / Revised: 18 November 2024 / Accepted: 20 November 2024 / Published: 22 November 2024
(This article belongs to the Section Clinical Research of Cancer)
Dorobisz et al. published an interesting paper entitled “Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site” [1]. We would like to present our comment from the perspective of bacteria researchers. The influence of the microbiome has been attracting attention in recent years [1]. Dorobisz et al.’s viewpoint is excellent, but their analysis and interpretation leave room for improvement. Many researchers have reported that Fusobacterium and Porphyromonas are often detected in the presence of cancer, and Streptococcus and Lactobacillus are common bacteria living in the oral cavity and are suspected to be related to inflammation and oral cancer.
Dorobisz et al. considered the following: “In the discussed study, patients with Cancer of unknown primary site (CUP) had a reduced amount of Streptococcus and Lactobacillus in the oral microbiome compared to the control group. Reduced amounts of Streptococcus was also associated with an increased risk of Radiation-induced oral mucositis (RIOM) and shortened survival rate in patients with CUP”. Their microbiome data only show percentages; their results may be a result of compositional data. In other words, due to the compositional data’s nature, an increase in a specific component will result in a decrease in another [2]. Moreover, odds ratios are measures of association and are used for count data, but Dorobisz et al. used the index for compositional data [1]. Since Culture Results are count data, logistic regression analysis is possible. However, logistic regression analysis cannot be applied to microbiome analysis, which is a compositional data analysis [2]. The ratio of the lower limit to the upper limit of the 95% confidence interval is sometimes used as an index of the reliability of the odds ratio: 0.5 or more is acceptable, 0.25 or more is moderate, and less than 0.25 is unreliable. Considering the characteristics of the data and results presented by Dorobisz et al., we recommend combining several methods, such as correcting the total bacterial count using Culture Results and performing bacterial flora analysis. This will free us from the use of percentage data and reveal the truth.
We generally agree with Dorobisz et al. However, Dorobisz et al. have conducted much research, so we would like them to provide us with the results and their interpretations in a better way. In this way, they can achieve results that cannot be obtained through bacterial flora analysis alone, and we will uncover the truth.

Author Contributions

Writing—original draft preparation, T.I., M.K. and K.-i.S.; writing—review and editing, T.I. and A.H. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Dorobisz, K.; Dorobisz, T.; Pazdro-Zastawny, K. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416. [Google Scholar] [CrossRef] [PubMed]
  2. Itagaki, T.; Kobayashi, H.; Sakata, K.-i.; Miyamoto, I.; Hasebe, A.; Kitagawa, Y. Compositional Data and Microbiota Analysis: Imagination and Reality. Microorganisms 2024, 12, 1484. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Itagaki, T.; Kasai, M.; Sakata, K.-i.; Hasebe, A. Comment on Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416. Cancers 2024, 16, 3911. https://doi.org/10.3390/cancers16233911

AMA Style

Itagaki T, Kasai M, Sakata K-i, Hasebe A. Comment on Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416. Cancers. 2024; 16(23):3911. https://doi.org/10.3390/cancers16233911

Chicago/Turabian Style

Itagaki, Tatsuki, Machiko Kasai, Ken-ichiro Sakata, and Akira Hasebe. 2024. "Comment on Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416" Cancers 16, no. 23: 3911. https://doi.org/10.3390/cancers16233911

APA Style

Itagaki, T., Kasai, M., Sakata, K.-i., & Hasebe, A. (2024). Comment on Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416. Cancers, 16(23), 3911. https://doi.org/10.3390/cancers16233911

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop